Molecule Details
| InChIKey | IFFPICMESYHZPQ-UHFFFAOYSA-N |
|---|---|
| Compound Name | Prenylamine |
| Canonical SMILES | CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 4 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 6.69 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB04825 |
|---|---|
| Drug Name | Prenylamine |
| CAS Number | 390-64-7 |
| Groups | approved withdrawn |
| ATC Codes | C01DX52 C01DX02 |
| Description | Prenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias. |
Categories: Adrenergic Agents Agents causing hyperkalemia Amines Antiarrhythmic agents Bradycardia-Causing Agents Calcium Channel Blockers Calcium-Regulating Hormones and Agents Calmodulin, antagonists & inhibitors Cardiac Therapy Cardiovascular Agents Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Substrates Ethylamines Hydroxy Acids Membrane Transport Modulators Moderate Risk QTc-Prolonging Agents Neurotransmitter Agents Phenethylamines QTc Prolonging Agents Vasodilating Agents Vasodilators Used in Cardiac Diseases
Cross-references: BindingDB: 50017723 ChEBI: 8397 CHEMBL24072 ChemSpider: 9418 D02383 PubChem:9801 PubChem:46508663 RxCUI: 8674 Wikipedia: Prenylamine
Target Activities (4)
| Target | Gene | Organism | Category | Pfam | pChEMBL | Type | Source |
|---|---|---|---|---|---|---|---|
| Q12809 | KCNH2 | Homo sapiens | Human | PF00027 PF00520 PF13426 | 7.2 | IC50 | ChEMBL;BindingDB |
| P35498 | SCN1A | Homo sapiens | Human | PF00520 PF24609 PF06512 PF11933 | 6.5 | IC50 | ChEMBL;BindingDB |
| Q99250 | SCN2A | Homo sapiens | Human | PF00520 PF24609 PF06512 PF11933 | 6.5 | IC50 | ChEMBL |
| Q9NY46 | SCN3A | Homo sapiens | Human | PF00520 PF24609 PF06512 PF11933 | 6.5 | IC50 | ChEMBL |